Drug
Artenimol clinical trials
Also written Dihydroartemisinin.
- studies test it
- 91
- open now
- 10
- in phase 3
- 34
- first study started
- 2003
Keep track of what changes. Save the artenimol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
- DP
- 6
Studies by the year they started
91 studies that test it; most in 2010 (9)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 9 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 8 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 34
- Phase 4
- 30
- No phase
- 13
What it is tested for
Each study’s main condition, where its own words name it.
- Malaria
- 53
Who runs them
Industry 7 · Other 84
University of California, San Francisco (7) · London School of Hygiene and Tropical Medicine (7) · University of Oxford (7) · Liverpool School of Tropical Medicine (6) · Shanghai Zhongshan Hospital (4) · National Institute for Medical Research, Tanzania (4) · sigma-tau i.f.r. S.p.A. (3) · University of North Carolina, Chapel Hill (2)
Often tested with
Tested in the same studies.
Piperaquine (83) · Artemether, Lumefantrine Drug Combination (10) · Fanasil, pyrimethamine drug combination (9) · Amodiaquine (8) · Chloroquine (6) · Artesunate (5) · Primaquine (4) · Mefloquine (2)
Studies
Open first, then newest update. How each study uses artenimol is read from its arms, and is right about nine times in ten.
Testing it · 91
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community TransmissionNot yet recruitingPhase 4University of California, San FranciscoNCT07246525Written as dihydroartemisinin-piperaquine
- Focal Mass Drug Administration for the Prevention of Malaria in PregnancyRecruitingEarly Phase 1University of North Carolina, Chapel HillNCT07021430Written as Dihydroartemisinin Piperaquine
- Dihydroartemisinin for MAFLDRecruitingPhase 1/2The First Affiliated Hospital with Nanjing Medical UniversityNCT07679542Written as Dihydroartemisinin
- A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus ErythematosusNot yet recruitingPhase 2Kunming Pharmaceuticals, Inc.NCT07557927Written as Dihydroartemisinin tablets
- Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium VivaxNot yet recruitingNot applicableWalter Reed Army Institute of Research (WRAIR)NCT07533136Written as Dihydroartemisinin-piperaquine (DHA-PPQ)
- Perennial Malaria Chemoprevention in the Malaria Vaccine EraNot yet recruitingPhase 4Stanford UniversityNCT07322068Written as Dihydroartemisinin Piperaquine
- Safety of Antimalarials in the FIRst trimEsterRecruitingPhase 3Liverpool School of Tropical MedicineNCT06962319Written as dihydroartemisinin-piperaquine (DP)
- Efficacy of Dihydroartemisinin for Treating Acne VulgarisRecruitingEarly Phase 1Shanghai Zhongshan HospitalNCT07007078Written as dihydroartemisinin
- Dihydroartemisinin for the Treatment of Polycystic Ovary SyndromeRecruitingPhase 2Shanghai Zhongshan HospitalNCT06842524Written as Dihydroartemisinin
- Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina FasoRecruitingPhase 3Malaria ConsortiumNCT05946642Written as Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)
- IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe FloodingActive, not recruitingNot applicableUniversity of North Carolina, Chapel HillNCT06870344Written as Dihydroartemisinin piperaquine
- CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal CancerActive, not recruitingPhase 2Shanghai Changzheng HospitalNCT07801352Written as Dihydroartemisinin
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, MalawiCompletedPhase 4Liverpool School of Tropical MedicineNCT06083688Written as Dihydroartemisinin-Piperaquine
- The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination TherapyCompletedPhase 4Infectious Diseases Research Collaboration, UgandaNCT06347471Written as Dihydroartemisinin-Piperaquine
- Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP)Active, not recruitingPhase 3Grant Dorsey, M.D, Ph.D.NCT04978272Written as Dihydroartemisinin-piperaquine (DP)
- Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of AntimalarialsActive, not recruitingPhase 2/3Johns Hopkins Bloomberg School of Public HealthNCT04009343Written as Dihydroartemisinin-piperaquine
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in UgandaCompletedPhase 3Grant Dorsey, M.D, Ph.D.NCT04336189Written as Dihydroartemisinin-piperaquine (DP)
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in MozambiqueCompletedPhase 4Centro de Investigacao em Saude de ManhicaNCT05343312Written as DHP
- Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in PregnancyActive, not recruitingPhase 3Menzies School of Health ResearchNCT05426434Written as Dihydroartemisinin-Piperaquine (DP)
- Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, EthiopiaActive, not recruitingPhase 3PATHNCT06516042Written as Dihydroartemisinin-piperaquine
See all 91 studies that test artenimol →
Given in every arm · 10 — artenimol is usual care beside what is tested
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated MalariaNot yet recruitingPhase 4Curtin UniversityNCT07403643Written as Dihydroartemisinin-piperaquine (DHA-PPQ)
- Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)CompletedPhase 2London School of Hygiene and Tropical MedicineNCT04609098Written as Dihydroartemisinin/Piperaquine
- Adjunctive Ivermectin Mass Drug Administration for Malaria ControlStatus unknownPhase 3London School of Hygiene and Tropical MedicineNCT04844905Written as Dihydroartemisinin-piperaquine
- Malaria Elimination Pilot Study in Military Forces in CambodiaStatus unknownPhase 4Armed Forces Research Institute of Medical Sciences, ThailandNCT02653898Written as DHA-PIP
- Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in CambodiaCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02612545Written as Dihydroartemisinin-piperaquine (DHA-PPQ)
- Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding StudyCompletedPhase 2Liverpool School of Tropical MedicineNCT02511353Written as dihydroartemisinin-piperaquine
- Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic CarriersCompletedPhase 3London School of Hygiene and Tropical MedicineNCT01838902Written as DHA-PPQ
- Delivery of Malaria Chemoprevention in the Post-discharge Management of Children With Severe Anaemia in MalawiStatus unknownPhase 3Kamuzu University of Health SciencesNCT02721420Written as dihydroartemisinin-piperaquine
- Safety and Tolerability of Low Dose PrimaquineCompletedPhase 4Malaria ConsortiumNCT02434952Written as Dihydroartemisinin piperaquine (DHA PP)
- Phase2a Primaquine Dose Escalation StudyCompletedPhase 2University of California, San FranciscoNCT01743820Written as dihydroartemisinin-piperaquine
As the comparator · 8 — what is tested is compared with artenimol
- Southeast Asia Dose Optimization of TafenoquineRecruitingPhase 4University of OxfordNCT04704999Written as Dihydroartemisinin 40 mg-Piperaquine 320 mg
- Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West PapuaCompletedPhase 2Syamsudin Abdillah,Ph.D, Pharm DNCT06036030Written as Dihydroartemisinin
- Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum MalariaCompletedPhase 1HuLowNCT02614404Written as Dihydroartemisinin-piperaquine
- Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum TransmissionCompletedPhase 2/3London School of Hygiene and Tropical MedicineNCT04049916Written as Dihydroartemisinin/Piperaquine
- Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant ParasitesStatus unknownPhase 2Nurex S.r.l.NCT03697668Written as Dihydroartemisinin-piperaquine
- Safety, Tolerability, Pharmacokinetics and Efficacy of ARCOCompletedPhase 4Ifakara Health InstituteNCT01930331Written as dihydroartemisinin/piperaquine phosphate
- Phase 2 Efficacy Study of Primaquine and Methylene BlueCompletedPhase 2University of California, San FranciscoNCT02831023Written as Dihydroartemisinin-piperaquine
- Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:CompletedPhase 4Institut Pasteur, CambodiaNCT02118090Written as DHA-PP
Codes
What other systems call artenimol · ClinicalTrials.gg INT003114
- MeSH (NLM) C039060artenimolConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6A9O50735XARTENIMOLConfirmed FDA, NLM
- NCI Thesaurus C87432ArtenimolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C039060 | artenimol | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6A9O50735X | ARTENIMOL | Confirmed FDA, NLM |
| NCI Thesaurus | C87432 | Artenimol | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.